x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011690
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ACP/NDUFAB1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NDUFAB1 |
| UniProt No. | O14561 |
| Gene ID | 4706 |
| Gene Description | Mitochondrial acyl carrier protein is an essential component in fatty acid biosynthesis in mitochondria. It is also known as NADH-ubiquinone oxidoreductase subunit AB1, a complex I subunit in the electron transport chain. NDUFAB1 regulates energy and reactive oxygen species metabolism in mitochondria by coordinating the assembly of ETC complexes I, II, and III, and supercomplexes. Studies show that overexpression of this protein protects the heart from ischemia-reperfusion injury in mice as well as protects mice from insulin resistance and obesity. In addition, NDUFAB1 mRNA levels are upregulated in pancreatic ductal adenocarcinoma compared with normal pancreatic ductal tissues. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
